Abstract:Hereditary hemochromatosis (HH) is a non-transfusional genetic iron overload (IO) disease wherein patients are not able to regulate dietary iron absorption, which ultimately leads to excess cellular iron accumulation. Preventative measures for HH mainly include phlebotomy and asking patients to minimize dietary iron intake. To investigate alternative iron reduction strategies, we report on prophylactic non-absorbable polymer-deferoxamine (DFO) conjugates capable of chelating and reducing excessive gut uptake of dietary iron. Three different sizes of the conjugates (56 nm, 256 nm, and 7.4 μm) were prepared, and their physicochemical properties, transit times in the gut under fed/fasted conditions, acute safety, and efficacy at reducing iron absorption in a dietary iron-overload mouse model were investigated. The conjugates were synthesized through reverse phase water-in-oil (w/o) emulsions, followed by conjugation of DFO to the resulting polymer scaffolds. In vitro studies using Caco-2 transwell assays showed that the conjugates could not permeate across the monolayer, were poorly endocytosed, and did not induce cellular toxicity. In vivo mouse studies via oral gavage demonstrated that polymer-DFO conjugates remained in the gastrointestinal (GI) tract for up to 12 h and significantly prevented escalation of serum ferritin levels and excess liver iron accumulation. Ex vivo images of the duodenum suggest that nanometer-sized conjugates (56 and 246 nm) perform better at chelating dietary iron based on longer retention times (i.e., entrapment in the villi of the duodenum) and an overall slower transit from the GI tract compared to larger micron-sized (7.4 μm) conjugates. Overall, nanometer-sized polymer-DFO conjugates were orally non-absorbable, appeared safe, and were more efficacious at reducing dietary iron absorption when taken with non-heme containing food.

From Small Deferiprone to Macromolecular Micelles: Self-assembly Enhances Iron Chelation.

A Small Molecular “albumin Hitchhiking” Deferoxamine Conjugate Improved Iron Clearance Efficacy

Polymeric Nanoparticles Enhance the Ability of Deferoxamine to Deplete Hepatic and Systemic Iron

New Deferric Amine Compounds Efficiently Chelate Excess Iron to Treat Iron Overload Disorders and to Prevent Ferroptosis

Deferasirox-TAT(47–57) peptide conjugate as a water soluble, bifunctional iron chelator with potential use in neuromedicine

A DFX-based iron nanochelator for cancer therapy

Oral Non-absorbable Polymer-Deferoxamine Conjugates for Reducing Dietary Iron Absorption

Melanin Nanoparticles As an Endogenous Agent for Efficient Iron Overload Therapy

Design and Synthesis of Novel Pegylated Iron Chelators with Decreased Metabolic Rate

A Water-Soluble Chitosan Derivative for the Release of Bioactive Deferoxamine

Natural polyphenol-based nanoparticles for the treatment of iron-overload disease

CN128: A New Orally Active Hydroxypyridinone Iron Chelator.

Cell Permeable Imidazole-Desferrioxamine Conjugates: Synthesis and In Vitro Evaluation

Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine

Chiral Polymer Micelles Alleviate Adriamycin Cardiotoxicity Via Iron Chelation and Ferroptosis Inhibition

Carrier-Free Deferoxamine Nanoparticles Against Iron Overload in Brain

PEGylation of Deferoxamine for Improving the Stability, Cytotoxicity, and Iron-Overload in an Experimental Stroke Model in Rats

In vitro studies of deferasirox derivatives as potential organelle-targeting traceable anti-cancer therapeutics

Amphetamine-like Deferiprone and Clioquinol Derivatives as Iron Chelating Agents

Magnetically Guided Delivery of DHA and Fe Ions for Enhanced Cancer Therapy Based on Ph-Responsive Degradation of DHA-loaded Fe 3 O 4 @C@mil-100(Fe) Nanoparticles

Fe-Mediated Self-Assembled Nanodrug for Tumor Microenvironment Activated Synergistic Ferroptosis-Based-Chemodynamic/Chemo Therapy and Magnetic Resonance Imaging